Cargando…
Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
BACKGROUND: In sub-Saharan Africa, severely immunocompromised HIV-infected individuals have a high risk of mortality during the first few months after starting antiretroviral therapy (ART). We hypothesise that universally providing ready-to-use supplementary food (RUSF) would increase early weight g...
Autores principales: | Mallewa, Jane, Szubert, Alexander J, Mugyenyi, Peter, Chidziva, Ennie, Thomason, Margaret J, Chepkorir, Priscilla, Abongomera, George, Baleeta, Keith, Etyang, Anthony, Warambwa, Colin, Melly, Betty, Mudzingwa, Shepherd, Kelly, Christine, Agutu, Clara, Wilkes, Helen, Nkomani, Sanele, Musiime, Victor, Lugemwa, Abbas, Pett, Sarah L, Bwakura-Dangarembizi, Mutsa, Prendergast, Andrew J, Gibb, Diana M, Walker, A Sarah, Berkley, James A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932190/ https://www.ncbi.nlm.nih.gov/pubmed/29653915 http://dx.doi.org/10.1016/S2352-3018(18)30038-9 |
Ejemplares similares
-
Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial
por: Siika, Abraham, et al.
Publicado: (2018) -
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
por: Kityo, Cissy, et al.
Publicado: (2018) -
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial
por: Post, Frank A, et al.
Publicado: (2018) -
Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
por: Prendergast, Andrew J., et al.
Publicado: (2016) -
Prevalence of Lipodystrophy and Metabolic Abnormalities in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy
por: Bwakura-Dangarembizi, Mutsawashe, et al.
Publicado: (2015)